AU2008287427B2 - Cancer treatment using humanized antibodies that bind to EphB4 - Google Patents

Cancer treatment using humanized antibodies that bind to EphB4 Download PDF

Info

Publication number
AU2008287427B2
AU2008287427B2 AU2008287427A AU2008287427A AU2008287427B2 AU 2008287427 B2 AU2008287427 B2 AU 2008287427B2 AU 2008287427 A AU2008287427 A AU 2008287427A AU 2008287427 A AU2008287427 A AU 2008287427A AU 2008287427 B2 AU2008287427 B2 AU 2008287427B2
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen binding
binding fragment
deimmunized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008287427A
Other languages
English (en)
Other versions
AU2008287427A1 (en
Inventor
Francis Joseph Carr
Parkash Gill
Timothy David Jones
Simon William Keen
Valery Krasnoperov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Publication of AU2008287427A1 publication Critical patent/AU2008287427A1/en
Application granted granted Critical
Publication of AU2008287427B2 publication Critical patent/AU2008287427B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008287427A 2007-08-13 2008-08-11 Cancer treatment using humanized antibodies that bind to EphB4 Ceased AU2008287427B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96449607P 2007-08-13 2007-08-13
US60/964,496 2007-08-13
PCT/US2008/009619 WO2009023185A1 (en) 2007-08-13 2008-08-11 Cancer treatment using humanized antibodies that bind to ephb4

Publications (2)

Publication Number Publication Date
AU2008287427A1 AU2008287427A1 (en) 2009-02-19
AU2008287427B2 true AU2008287427B2 (en) 2014-10-09

Family

ID=40029214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008287427A Ceased AU2008287427B2 (en) 2007-08-13 2008-08-11 Cancer treatment using humanized antibodies that bind to EphB4

Country Status (8)

Country Link
US (1) US8975377B2 (enExample)
EP (1) EP2185594B1 (enExample)
JP (1) JP5749009B2 (enExample)
CN (1) CN102083861B (enExample)
AU (1) AU2008287427B2 (enExample)
BR (1) BRPI0815399A2 (enExample)
CA (1) CA2696164C (enExample)
WO (1) WO2009023185A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
HRP20210680T1 (hr) * 2014-07-10 2021-06-11 Bioarctic Ab POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
ES2882276T3 (es) * 2015-04-14 2021-12-01 Academia Sinica Anticuerpo humano anti-VEGFR2 para terapia antiangiogénica y terapia dirigida contra el cáncer
KR20240056644A (ko) * 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
CN114409792B (zh) * 2021-12-01 2022-08-12 中山大学附属第五医院 抗EphB4纳米抗体
KR20240163163A (ko) * 2022-03-28 2024-11-18 코히러스 바이오사이언시스, 인크. 항-ilt4 조성물 및 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20060121042A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE68703T1 (de) 1984-02-08 1991-11-15 Cetus Corp Toxinkonjugate.
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4815397A (en) * 1986-07-28 1989-03-28 Warren Engineering Corporation Sludge treatment apparatus
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
CA2111006C (en) 1991-06-21 2008-04-08 Andrew D. Boyd A novel receptor-type tyrosine kinase and use thereof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
CA2128722A1 (en) 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
AU685765B2 (en) 1992-11-13 1998-01-29 Amgen, Inc. (Eck) receptor ligands
US5512591A (en) 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (es) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
US5698413A (en) 1993-05-05 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5624899A (en) 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
AU3144195A (en) 1994-07-26 1996-02-22 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
WO1996013518A1 (en) 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US5837534A (en) 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6413730B1 (en) 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
JP3417803B2 (ja) * 1997-07-07 2003-06-16 リンテック株式会社 ハードコートシート
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
EP1019080A2 (en) 1997-10-02 2000-07-19 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU8788998A (en) 1998-10-02 2000-04-06 Universite Paris 7 Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
ATE293989T1 (de) 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
WO2002011785A2 (en) 2000-08-03 2002-02-14 The University Of Utah Research Foundation Manipulation of arterial-venous identity
WO2002026827A1 (en) 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
CA2429460A1 (en) 2000-11-20 2002-05-23 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US6958140B2 (en) 2001-01-26 2005-10-25 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
EP1358211A2 (en) 2001-01-31 2003-11-05 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
WO2002079382A2 (en) 2001-03-30 2002-10-10 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1531554A (zh) * 2001-06-26 2004-09-22 ��������ҽѧ���޹�˾ 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2452578A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
IL159422A0 (en) * 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US6619055B1 (en) * 2002-03-20 2003-09-16 Honeywell International Inc. Security system with wireless thermostat and method of operation thereof
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
JP2004053694A (ja) 2002-07-16 2004-02-19 Sharp Corp 表示装置、文字・図形表示制御方法、文字・図形表示プログラムおよび可読記録媒体
US20040023420A1 (en) * 2002-08-02 2004-02-05 Macromix International Co., Ltd. Method for reduced photoresist usage
AU2002951409A0 (en) 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
EP1606305A4 (en) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
WO2004091375A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
DE10325166B4 (de) * 2003-06-04 2006-11-23 Graf von der Schulenburg-Wolfsburg, Günzel, Dr. Gleisaufbau für schienengebundene Fahrzeuge, insbesondere Eisenbahnen
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
CN1905899B (zh) 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
EP2388271A3 (en) 2005-02-03 2012-08-01 Antitope Limited Human Antibodies and Proteins
EP1973950B1 (en) * 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
WO2008042941A2 (en) 2006-10-04 2008-04-10 Medimmune, Llc Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
EP2137216A2 (en) 2007-03-12 2009-12-30 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20050249736A1 (en) * 2003-03-12 2005-11-10 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
US20060121042A1 (en) * 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAMSCHRODER, M.M. et al. 'Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.' Molecular Immunology. 2007. 44: 3049-3060 *

Also Published As

Publication number Publication date
EP2185594B1 (en) 2016-04-06
WO2009023185A1 (en) 2009-02-19
CN102083861A (zh) 2011-06-01
US8975377B2 (en) 2015-03-10
JP5749009B2 (ja) 2015-07-15
CA2696164A1 (en) 2009-02-19
JP2010536751A (ja) 2010-12-02
HK1157798A1 (zh) 2012-07-06
AU2008287427A1 (en) 2009-02-19
CN102083861B (zh) 2016-04-13
US20090196880A1 (en) 2009-08-06
EP2185594A1 (en) 2010-05-19
BRPI0815399A2 (pt) 2019-09-24
CA2696164C (en) 2018-06-12

Similar Documents

Publication Publication Date Title
RU2766582C2 (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
AU2008338591B8 (en) Binding molecules to the human OX40 receptor
US8975377B2 (en) Cancer treatment using humanized antibodies that bind to EphB4
US20200055937A1 (en) Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
US11248049B2 (en) Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
JP2023529010A (ja) Ｔｎｆｒ２に結合する抗体およびその用途
AU2005224081B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2021228746A1 (en) A novel antibody binding specifically to human ceacam1/3/5 and use thereof
US8981062B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
HK1157798B (en) Cancer treatment using humanized antibodies that bind to ephb4
AU2018202095B2 (en) Binding Molecules to the Human OX40 Receptor
AU2014202213B2 (en) Binding Molecules to the Human OX40 Receptor
HK1101695B (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
NZ584117A (en) Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired